PASTIC Dspace Repository

Pharmacokinetic and Bioavailability Studies of Commercially Available Simvastatin Tablets in Healthy and Moderately Hyperlipidemic Human Subjects

Show simple item record

dc.contributor.author MAHMOOD AHMAD
dc.contributor.author MUHAMMAD QAMAR-UZ-ZAMAN
dc.contributor.author ASADULLAH MADNI
dc.contributor.author MUHAMMAD USMAN
dc.contributor.author MUHAMMAD ATIF
dc.contributor.author NAVEED AKHTAR
dc.contributor.author GHULAM MURTAZA
dc.date.accessioned 2023-08-30T07:48:26Z
dc.date.available 2023-08-30T07:48:26Z
dc.date.issued 2011-02-06
dc.identifier.citation AHMED, M., AKHTAR, N., ATIF, M., QAMAR-UZ-ZAMAN, M. U. H. A. M. M. A. D., MURTAZA, G., USMAN, M., & MADNI, A. (2011). Pharmacokinetic and bioavailability studies of commercially available simvastatin tablets in healthy and moderately hyperlipidemic human subjects. Journal of the Chemical Society of Pakistan, 33(6), 49. en_US
dc.identifier.issn 0253-5106
dc.identifier.uri http://142.54.178.187:9060/xmlui/handle/123456789/19574
dc.description.abstract Simvastatin, an analogue of Lovastatin, is a HMG.CoA reductase inhibitor. It is widely used in the treatment of hyperlipidemia and coronary heart disease (CHD) with low incidence of myopathy and rhabdomyolysis. As these diseases may alter the pharmacokinetics of drugs, the present study was aimed to elaborate the variation in the pharmacokinetics and bioavailability of simvastatin in local healthy and moderately hyperlipidemic population. Open, single dose and parallel design was applied to study. A total of 36 male volunteers were used for healthy and moderately hyperlipidemic groups (n = 18 for each) in this study on the basis of screening procedures, body chemistry and physical examination. Simvastatin 40 mg tablets (Saista 40, Bosch, Pakistan) were administered to over-night fasted volunteers. Blood samples were collected before dosing (zero time) and at regular intervals of time. The plasma samples were processed through a liquid-liquid extraction procedure and assayed by using HPLC consisting reversed phase C18 column (ZORBAX, 4.6 x 150 mm, 5 µm), UV detector set at 238 nm. The mobile phase consisted of the mixture of 0.025 M sodium dihydrogen phosphate (pH 4.5): acetonitrile (35: 65, v/v) which was pumped at a flow rate of 1.5 mL.min-1. The retention time of simvastatin was 7.5 minutes. The plasma drug concentration-time profiles of both groups were found significantly (P < 0.05) identical. The data was analyzed by using Kinetica® version 4.4 according to non-compartment model of pharmacokinetic analysis. There was statistically no significant (P > 0.05) difference between the values of following pharmacokinetic parameters in healthy and hyperlipidemic volunteers i.e. Cmax, tmax, AUC0-∞, AUMC0-∞, MRT, t1/2, Clt and Ke. This study confirmed no significant (P > 0.05) difference in pharmacokinetics and bioavailability parameters after the administration of a single oral dose of 40 mg simvastatin (cholesterol lowering drug) to healthy and moderately hyperlipidemic volunteers. en_US
dc.description.sponsorship The chemical society of Pakistan is an approved society from the PSF en_US
dc.language.iso en en_US
dc.publisher Karachi: International Centre for Chemical and Biological Sciences, H.E.J. Research Institute of Chemistry, University of Karachi en_US
dc.title Pharmacokinetic and Bioavailability Studies of Commercially Available Simvastatin Tablets in Healthy and Moderately Hyperlipidemic Human Subjects en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account